CD45RB Antibody [PTPRC/1147] | 33-300

CD45RB Antibody [PTPRC/1147] | 33-300 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Human B lymphocytes were used as immunogen for this CD45RB antibody.

Research Area: Cancer, Immunology, Neuroscience, Signal Transduction

Tested Application: Flow, IHC, IF, WB

Application: Flow Cytometry: 0.5-1 ug/million cells
Immunofluorescence: 0.5-1 ug/ml
Immunohistology (FFPE) : 0.5-1.0 ug/ml for 30 minutes at RT (1)
Western blot: 0.5-1.0 ug/ml
Prediluted format : incubate for 30 min at RT (2)
Due to variation in protocol and secondary antibody used, the CD45RB antibody may need to be titered for optimal performance.

1. FFPE staining requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: PTPRC/1147

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Receptor-type tyrosine-protein phosphatase C, Leukocyte common antigen, L-CA, T200, CD45, PTPRC, CD45

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: CD45R, also designated CD45 and PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4) , CD45RB (exon 5) , CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out) . The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45RB is expressed on mature B-lymphocytes and the majority of lymphomas and leukemias of B-cell origin. This antigen is also expressed on the surface of cells of myeloid lineage.